Restless legs syndrome: pathophysiology, clinical presentation and management (Q37763512)

22 August 2017

1 reference

title

Restless legs syndrome: pathophysiology, clinical presentation and management (English)

1 reference

22 August 2017

1 reference

restless legs syndrome

1 reference

1

Claudia Trenkwalder

1 reference

22 August 2017

2

Walter Paulus

1 reference

PubMed ID

20531433

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

22 August 2017

Nature Reviews Neurology

1 reference

22 August 2017

6

1 reference

22 August 2017

6

1 reference

22 August 2017

337-346

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2010.55

22 August 2017

0 references

cites work

Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Motor system excitability in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

MRI measurement of brain iron in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Ropinirole for restless legs syndrome: a placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Restless legs syndrome improved by pramipexole: a double-blind randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Dopaminergic treatment of restless legs and rebound phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

The use of triazolam in older patients with periodic leg movements, fragmented sleep, and daytime sleepiness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Why do restless legs occur at rest?--pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Empirical evaluation of the accuracy of diagnostic criteria for Restless Legs Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Comparison of sleep variables between chronic widespread musculoskeletal pain, insomnia, periodic leg movements syndrome and control subjects in a clinical sleep medicine practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Validation of the "L-DOPA test" for diagnosis of restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Effects of immobility on sensory and motor symptoms of restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Sleep laboratory diagnosis of restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Correlation between putative indicators of primary restless legs syndrome severity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Circadian variation of the effects of immobility on symptoms of restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Investigation into the correlation between sensation and leg movement in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Circadian rhythm of restless legs syndrome: relationship with biological markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Augmentation as a treatment complication of restless legs syndrome: concept and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Validation of the Johns Hopkins restless legs severity scale.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Correlation between rating scales and sleep laboratory measurements in restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Periodic leg movements during sleep in the elderly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Periodic Limb M[ovements in Sleep in Community-Dwelling Elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Periodic leg movements during sleep and periodic limb movement disorder in patients presenting with unexplained insomnia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Stud

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Periodic leg movements in RLS patients as compared to controls: Are there differences beyond the PLM index?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Computer-assisted detection of nocturnal leg motor activity in patients with restless legs syndrome and periodic leg movements during sleep.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Practice Parameters for the Indications for Polysomnography and Related Procedures: An Update for 2005

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Consensus statement from the German Sleep Society: indications for performing polysomnography in the diagnosis and treatment of restless leg syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

PLM detection by actigraphy compared to polysomnography: a validation and comparison of two actigraphs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

A genetic risk factor for periodic limb movements in sleep

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Improving RLS diagnosis and severity assessment: polysomnography, actigraphy and RLS-sleep log.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Validation of the Hopkins telephone diagnostic interview for restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Dopamine and the spinal cord in restless legs syndrome: Does spinal cord physiology reveal a basis for augmentation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Motoneuron excitability: the importance of neuromodulatory inputs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Serotonin affects transcranial direct current-induced neuroplasticity in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Dopamine agonists restore cortical plasticity in patients with idiopathic restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Delayed L-DOPA-induced hyperalgesia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Changes in cortical dopamine D1 receptor binding associated with cognitive training.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Lack of D2 receptor mediated regulation of dopamine synthesis in A11 diencephalospinal neurons in male and female mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Cerebral generators involved in the pathogenesis of the restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Cortical grey matter alterations in idiopathic restless legs syndrome: An optimized voxel-based morphometry study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Cerebral white matter alterations in idiopathic restless legs syndrome, as measured by diffusion tensor imaging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Bilateral thalamic gray matter changes in patients with restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Lack of specific gray matter alterations in restless legs syndrome in elderly subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Voxel-based morphometry in unmedicated patients with restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Influence of cabergoline on motor excitability in patients with restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Ferritin subunits in CSF are decreased in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Circadian changes in CSF dopaminergic measures in restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

The role of iron in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Pathophysiology of restless legs syndrome: evidence for iron involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Iron-deficiency sensitizes mice to acute pain stimuli and formalin-induced nociception

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Projections of diencephalic dopamine neurons into the spinal cord in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Abnormal H-reflexes in periodic limb movement disorder; impact on understanding the pathophysiology of the disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Idiopathic restless legs syndrome: abnormalities in central somatosensory processing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Cognitive behavioural group therapy to improve patients' strategies for coping with restless legs syndrome: a proof-of-concept trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Iron status and restless legs syndrome in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Augmentation in restless legs syndrome is associated with low ferritin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Augmentation of the restless legs syndrome with carbidopa/levodopa.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

One‐year treatment with standard and sustained‐release levodopa: Appropriate long‐term treatment of restless legs syndrome?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Efficacy and safety of pramipexole in restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Restless legs syndrome augmentation associated with tramadol.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Augmentation of restless legs syndrome with long-term tramadol treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Long-term follow-up on restless legs syndrome patients treated with opioids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Pregabalin in restless legs syndrome with and without neuropathic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Restless legs syndrome induced by topiramate: two more cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Clonazepam and vibration in restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Double-blind evaluation of clonazepam on periodic leg movements in sleep

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Zolpidem in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Amantadine is beneficial in restless legs syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

The MOS 36-ltem Short-Form Health Survey (SF-36)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.55

Practice parameters for the indications for polysomnography and related procedures: an update for 2005.

31 March 2020

1 reference

12 December 2020

L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.

1 reference

12 December 2020

Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome.

1 reference

12 December 2020

Periodic leg movements in sleep with restless legs syndrome: effect of clonazepam treatment

1 reference

12 December 2020

Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial.

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome.

1 reference

12 December 2020

A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene.

1 reference

12 December 2020

L-DOPA/carbidopa for nocturnal movement disorders in uremia.

1 reference

12 December 2020

L-dopa induces opposing effects on pain in intact rats: (-)-sulpiride, SCH 23390 or alpha-methyl-DL-p-tyrosine methylester hydrochloride reveals profound hyperalgesia in large antinociceptive doses.

1 reference

12 December 2020

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2010.55

1 reference

22 August 2017

1 reference

PubMed ID

20531433